Mendelian randomisation highlights hypothyroidism as a causal determinant of idiopathic pulmonary fibrosis

Yanan Zhang\textsuperscript{a,b}, Meng Zhao\textsuperscript{c,d}, Ping Guo\textsuperscript{a,b}, Yanjun Wang\textsuperscript{a,b}, Lu Liu\textsuperscript{a,b}, Jinghua Zhao\textsuperscript{e}, Ling Gao\textsuperscript{c,d}, Zhongshang Yuan\textsuperscript{a,b,h}, Fuzhong Xue\textsuperscript{a,b,h,s}, Jiajun Zhao\textsuperscript{c,d,s}

\textsuperscript{a}Department of Biostatistics, School of Public Health, Cheloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China
\textsuperscript{b}Institute for Medical Dataology, Shandong University, Jinan, Shandong, 250003, China
\textsuperscript{c}Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China
\textsuperscript{d}Department of Endocrinology, Shandong Provincial Hospital, Cheloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China
\textsuperscript{e}Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China
\textsuperscript{f}Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a condition in which the lungs become scarred and breathing is increasingly difficult, and occurs primarily in older adults with unknown etiology\cite{19} and a median survival of 3.8 years\cite{2}. In recent years, IPF has become more prevalent and the incidence is on the rise\cite{3}. One consensus regarding IPF is that damage to the alveolar epithelium and an aberrant wound-healing response cause widespread deposition of dense fibrotic tissue, reduce the lung compliance, and inhibit gas transfer. Treatment options in IPF are limited thus far. Consequently, understanding of comorbidities in the IPF patient population, in particular their relationship, can greatly improve clinical practice including quality of life and potentially survival\cite{5}. Comorbidities frequently occurring in IPF include both respiratory (e.g., chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), pulmonary hypertension (PH), and lung cancer) and non-respiratory (e.g., ischemic heart disease (IHD), atherosclerosis (AS), type 2 diabetes (T2D), gastroesophageal reflux disease (GERD), and hypothyroidism) diseases\cite{5, 6}. Among these, the association between hypothyroidism and IPF is of particular interest: a retrospective case-control study\cite{7} showed that hypothyroidism was significantly associated with IPF even after adjusting for body mass index, smoking, diabetes, GERD, and chronic corticosteroid.
Research in context

Evidence before this study

We searched PubMed on October 3, 2021, with the search terms (“idiopathic pulmonary fibrosis” OR “pulmonary fibrosis”) AND (“hypothyroidism” OR “thyroid function” OR “thyroid hormones”) and without date restrictions. We identified 50 PubMed-indexed articles in total, including in particular a case-control study which reported the association between hypothyroidism and idiopathic pulmonary fibrosis (IPF) after adjusting for body mass index, smoking, diabetes, gastroesophageal reflux, and chronic corticosteroid therapy. Several observational studies also illustrated the relationship between thyroid function and pulmonary fibrosis. The relationship between hypothyroidism and IPF is bound to be controversial due to a range of known and unknown confounders, and the underlying mechanisms may be complex. The causality of hypothyroidism on IPF is yet to be established.

Added value of this study

We establish a causal relationship between hypothyroidism and IPF through a two-sample Mendelian randomisation (MR) framework using large-scale genome-wide association studies (GWASs) summary statistics. Findings were verified using an independent validation dataset, as well as through different MR methods with different model assumptions. Bidirectional MR analyses also indicated no reverse causation. Multivariable MR analysis showed hypothyroidism had the largest marginal inclusion probability compared with other comorbidities of IPF.

Implications of all the available evidence

Our study was the first attempt shedding light on the directional causal relationship between hypothyroidism and IPF, adding to existing knowledge in etiology of IPF. It will also facilitate revealing pathogenic pathways and planning future studies.

Factors and disease outcomes [12]. Two-sample MR estimates and tests for the causal effect of an exposure on an outcome measured in two separate studies with no sample overlap [13]. In this study, we investigate the causal relationship between genetically predicted hypothyroidism and IPF in the MR framework using publicly available GWAS summary statistics. The results can provide additional evidence in the etiology of IPF.

2. Methods

2.1. Study design

A two-sample MR was firstly performed on the bi-directional causal relationship between hypothyroidism and IPF, followed by verification using an independent validation dataset as well as using different MR methods with different model assumptions. A multivariable MR based on Bayesian model averaging (MR-BMA) [14] was further conducted to see whether hypothyroidism remains to be selected as the true causal factor of IPF, given several other comorbidities of IPF.

2.2. GWAS data sources and instrument selection in univariable MR

Two-sample MR analyses were conducted using GWAS summary data. In total, we obtained three GWASs of hypothyroidism and one GWAS of IPF. All GWAS studies were restricted to unrelated individuals of European ancestry. In discovery analysis, we used the hypothyroidism GWAS from UK Biobank (UKBB) (data field 20002_1226) [15], which had the largest sample size (N=289,307 with 18,740 cases and 270,567 controls). UKBB is a large-scale population-based cohort study of half a million people aged between 40 and 69 years from the United Kingdom [16]. The hypothyroidism genetic association data were obtained from UKBB release 2 data in the Atlas of GWAS Summary Statistics (https://atlas.crg.cat/), where hypothyroidism was defined with self-reported history of hypothyroidism/myxedema. In validation analysis, we used the hypothyroidism GWAS data from the large GWAS study on thyroid function and dysfunction [17], with 3,440 cases and 49,983 controls, where hypothyroidism was defined with thyroid stimulating hormone levels above the cohort-specific reference range. In sensitivity analysis, another hypothyroidism GWAS from UKBB (data field 41204_E03), diagnosed with secondary ICD-10 with 244,890 individuals, was further analyzed to test the robustness against different illness code [15]. GWAS summary statistics on IPF was from the largest GWAS to date [18], derived from a meta-analysis on three previous IPF studies including the Chicago study [19], the Colorado Study [20,21], and the UK study [22]. The meta-analysis obtained a maximum sample size of up to 11,259 individuals (2,668 cases and 8,591 controls) for 10,790,934 well-imputed SNPs with minor allele count >10 in the three studies. Each study was separately conducted adjusting for the first 10 principal components to account for population structure. IPF cases from the studies are directly diagnosed using guidelines American Thoracic Society and European Respiratory Society guidelines [1,23,24] and had appropriate institutional review board or ethics approval. In addition, sample overlap between two datasets could bias the estimated causal effect [25], thus we conducted linkage disequilibrium score regression (LDSC) to assess sample overlap [26].

The MR framework uses independent instrumental SNPs as instrumental variables (IVs) for the exposure (e.g., hypothyroidism) to estimate and test the causal effect on the outcome (i.e., IPF). A standard MR analysis requires three model assumptions to hold [12] (Fig. 1a): (i) instruments are associated with the exposure of interest; (ii) instruments are not associated with any other confounders that may be associated with both exposure and outcome; (iii) instruments only influence the outcome by the path of exposure. A primary step of MR is to determine appropriate genetic variants to serve as valid
IVs for exposure. For UKBB hypothyroidism data used in discovery and sensitivity analysis, IVs were derived from lead SNPs reported by GWAS Atlas [https://atlas.ctglab.nl/traitDB]. For non-UKBB hypothyroidism data used in validation analysis, IVs were obtained through the clumping procedure of PLINK (version 1.90) \( r^2 < 0.01 \), where \( r^2 \) is a measure of linkage disequilibrium (LD), a non-random association in the occurrence of alleles at two loci[28]. Then, independent instrumental SNPs were harmonised with the outcome IPF GWAS summary statistics.

2.3. Instrument and variable selection in multivariable MR

Multivariable MR can be considered as an extension of standard univariable MR including multiple variables (Fig. 1b). We selected the large-scale GWAS of potential IPF-related factors including several comorbidities and smoking from two commonly used GWAS platforms: GWAS Atlas, https://atlas.ctglab.nl/traitDB, and Neale lab, http://www.nealelab.is/uk-biobank (Table 1). MR-BMA basically requires the independence among instrumental SNPs, OSA and GERD were removed since there were no independent SNPs left after the LD pruning using PLINK (version 1.90) \( r^2 < 0.001 \). Among the combination SNPs of all retained IPF-related factors, LD clumping was further used to re-determine the final instruments to satisfy the independence. Given another model assumption of multivariable MR is that it only included variables strongly instrumented by at least one instrumental SNP \( P<5 \times 10^{-8} \), COPD and lung cancer were further removed. Finally, hypothyroidism, IHD, CAD, T2D, and smoking were included in the MR-BMA model.

2.4. Statistical analysis

The \( F \) statistic (also known as the Cragg-Donald statistic) [29] was employed to evaluate the issue of weak instrument in MR analysis. MR inverse-variance weighted (MR-IVW) method was used [30] as the main analysis. Estimator is represented the weighted regression slope of the SNP-outcome effect on the SNP-exposure effect when the intercept is limited to zero. Several other MR methods with different model assumptions were performed to relax the assumption and address the pleiotropy effect: (i) the weighted median method, which can provide consistent estimates when at least half of the instruments used in the analysis are valid [31]. (ii) MR Robust Adjusted Profile Score (MR-RAPS) [32], which is robust to both systematic and idiosyncratic pleiotropy. (iii) MR-lasso [33], which penalizes the number of candidate instrumental SNPs to be used in the model. (iv) MR-IVW method using robust regression (MR-Robust) [33], which reduces the standard error of estimates. (v) leave-one-out (LOO) cross-validation analysis [34] and Mendelian Randomisation Pleiotropy RESidual Sum and Outlier (MR-PRESSO) analysis [35], which makes causal inference as well as outlier detection. Furthermore, we depicted diagnostic plots (e.g., funnel plot) to illustrate the MR results, which can detect visually directional pleiotropy using symmetry of graphical representations. A reverse causation analysis

---

**Figure 1.** Study design. (a) The causal diagram for standard Mendelian randomisation (MR) analysis, which involves instrumental variable (IV) and requires three assumptions. (b) Illustrative diagram of IV assumptions made in multivariable MR model. IPF, idiopathic pulmonary fibrosis; MR, Mendelian randomisation.
was carried out to exclude the possibility that IPF causally affected hypothyroidism using IPF-associated SNPs as IVs.

MR-BMA was a recently developed multivariable MR method whose major advantage over other methods lies in its ability to select the true causal determinants of an outcome from a set of candidate variables, no matter whether these variables are correlated or not [14]. The model posterior probability (PP) was calculated for each possible set of variables, which quantifies the possibility of the specific variables being a causal determinant of IPF risk. In addition, we computed the marginal inclusion probability (MIP) for the variable by summing up the models PP including the variable, representing the probability of causal association between the variable and IPF. The model-averaged causal effect of each variable on the IPF was finally obtained. Note that it was non-trivial to obtain the P-value significance level was set to be 0.05.

2.5. Ethics

Summary data was used and as such ethical approval was not required.

2.6. Role of funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, and writing of the report.

3. Results

3.1. Univariable two-sample MR analysis

3.1.1. Discovery analysis

To address the concern over bias in the estimated causal effect [25] due to overlapping samples in the hypothyroidism GWAS and IPF GWAS, LDSC was used to obtain an approximately zero intercept of genetic covariance 0.0013 (z-test, se=0.0052, P=0.80), indicating little or no impact from sample overlap on the two datasets [26]. A total of 84 IVs were identified in the hypothyroidism GWAS dataset (UKBB data field 20002_1226) (Supplementary Table 1), which explained about 2.15% phenotypic variation of hypothyroidism. The F statistics of all these IVs are above ten with an overall F statistic of 75.62, indicating that the weak instrument bias would not substantially influence the estimations of causal effects. The overall causal estimate supported the causality of hypothyroidism on IPF (Fig. 2), with an odds ratio (OR) of 1.125 (MR-IVW, 95% confidence interval [CI] 1.028-1.231; P=0.011), suggesting that self-reported history of hypothyroidism/ myxedema can lead to an average of 12.5% increase in the risk of IPF. Overall, the causal effect estimate of hypothyroidism on IPF from several MR methods were quite consistent. The relevant OR estimate was 1.101 (MR-Iasso, 95%CI 1.012-1.198; P=0.025), 1.111 (MR-Robust, 95%CI 0.997-1.237; P=0.057), 1.140 (MR-RAPS, 95%CI 1.003-1.215; P=0.042), 1.125 (MR-PRESSO, 95%CI 1.028-1.231; P=0.013) and 1.149 (weighted median method, 95%CI 1.010-1.308; P=0.034), respectively (Fig. 2). The MR-PRESSO analysis showed no significant horizontal pleiotropic outliers. The diagnostic funnel plot shows a visually apparent symmetry, which suggested that the causal estimates would possibly not suffer from the influence of directional pleiotropy. (Fig. 3a). In addition, LOO analysis also showed that no single instrumental SNP can influence the causal effect estimation (Fig. 3b).

3.1.2. Validation analysis

The intercept of the LDSC between two hypothyroidism GWASs from discovery and validation analysis is 0.0067 (z-test, se=0.0069, P=0.33), and it is -0.0003 (z-test, se=0.0049, P=0.95) between the validation hypothyroidism GWAS and the IPF GWAS, both indicating approximately no sample overlap [40]. Hence, this non-UOBH hypothyroidism dataset could serve as independent validation dataset and as well satisfy the requirement of exposure and outcome datasets with no sample overlap in two-sample MR. A total of nine independent IVs were finally screened in the independent validation hypothyroidism GWAS dataset [17] (Supplementary Table 2), which explained about 0.77% phenotypic variation of hypothyroidism. The F statistics of all these SNPs are above ten with an overall F statistic of 46.32, indicating less weak instrument bias. No significant causal effect can be detected by MR-JVW method. Further investigation showed that, among the nine SNPs, there were three SNPs having the pleiotropy (rs12449792, rs2983514, rs597808), which has been successfully detected by MR-PRESSO method. Consistently, all MR methods that were not robust to the pleiotropy effect failed to detect the causal associations, while the MR method that was robust to the pleiotropy effect successfully detected the causal effect of hypothyroidism on IPF, with the OR estimate being 1.215 (weighted median method, 95%CI 1.011-1.461; P=0.038), 1.229 (MR-PRESSO, 95%CI 1.102-1.369; P=0.014) (Supplement Figure 1). After removing the pleiotropic SNPs, the OR estimate was 1.229 (MR-IVW, 95%CI 1.054-1.432; P=0.008), 1.229 (MR-Iasso, 95%CI 1.054-1.430; P=0.008), 1.226 (MR-Robust, 95%CI 1.095-1.373; P<0.001), 1.231 (MR-RAPS, 95%CI 1.046-1.449; P=0.013), 1.229 (MR-PRESSO, 95%CI 1.103-1.369; P=0.014) and 1.229 (weighted median method, 95%CI 1.016-1.484; P=0.034), respectively (Fig. 2).
3.1.3. Sensitivity analysis

The results are robust to the hypothyroidism GWAS dataset with different illness code (UKBB data field 41204_E03) (Supplementary Table 3), with 45 valid instrumental SNPs being selected. All findings also supported the causal role of hypothyroidism in the development of IPF (Fig. 2). In bidirectional analyses, the IPF-hypothyroidism causal model was not significant (MR-IVW, OR=1.014; 95%CI 0.983-1.046; P=0.371), indicating no reverse causation.

3.2. Multivariable MR analysis based on BMA

In the MR-BMA analysis, 183 independent genome-wide significant SNPs were identified as valid IVs (Supplementary Table 4). Through model diagnostics, no influential but an outlying instrumental SNP, rs763053, was detected (Fig. 4). Our analysis was performed after removing the outlier (n=182). Table 2 presented the top ten models (i.e., sets of IPF-related factors) according to their model PP, as well as the MIP and the model-averaged causal effect estimate of the five IPF-related factors. Hypothyroidism had the strongest marginal evidence (MIP=0.397, FDR=0.025). Note that similar results were obtained when 183 IVs were included in the analysis (Supplementary Table 5).

4. Discussion

In the present study, we illustrated the causal effect of hypothyroidism on IPF under the two-sample MR framework. The results were verified using an independent validation dataset as well as through different MR methods with different model assumptions, suggesting the findings were robust and convincing. In addition, bidirectional analyses also indicated no reverse causation. The study took great advantage of an MR analysis using the genetic instruments and benefited from large sample size in the GWAS, containing 2,668 cases and 8,591 controls as the largest on IPF so far [18]. More importantly, the causal role of hypothyroidism in IPF remained even given other comorbidities of IPF in the multivariable MR model. Our study...
corroborated results from previous observational studies showing a relationship between hypothyroidism and pulmonary fibrosis [7–9].

The underlying mechanisms in the causative role of hypothyroidism in IPF may be quite complex. Several biological mechanisms might explain the effect. Previous studies have suggested that the state of hypothyroidism would reinforce oxidative stress [41,42], which is implicated to affect apoptosis of structural and inflammatory cells as well as alter the cytokine microenvironment balance and, hence, involving in the pathogenic pathways of IPF [43,44]. In addition, mitochondrial dysfunction and metabolic aberrations are possibly involved in pulmonary fibrosis [45]. Thyroid hormone, which regulates fundamental biological functions, is critical for maintenance of cellular homeostasis during stress responses [46]. In an animal study [47], anti-fibrosis properties and protection of alveolar epithelial cells of thyroid hormones suggest a pathway on the restoration of mitochondrial function, so thyroid hormone may be a potential treatment for pulmonary fibrosis. Furthermore, TGF-β would contribute to the development of IPF in expansion of the fibroblast and myofibroblast populations [48] by activating SMAD (mothers against decapentaplegic) transcription factors. An experimental study suggested that thyroid hormones could inhibit TGF-β signaling by antagonizing transcriptional activation of TGF-β/SMAD, which leads to attenuation of fibrotic responses [49], and thus may play a critical role in blocking the progression of IPF. In conclusion, hypothyroidism with a decrease in the synthesis and secretion of thyroid hormones [50], creates metabolic conditions that lead to antagonism transcriptional activation of TGF-β/SMAD, thus contributing to IPF pathogenesis.

Some limitations of this study should be considered. First, it should be noted that we used the summary data of self-reported hypothyroidism with non-cancer illness code from UKBB field 20002 in discovery analysis, rather than the summary data of hypothyroidism with diagnosis from main ICD-10 code. Indeed, in total we...
screened out 1,690 SNPs from the hypothyroidism GWAS data with diagnosis from main ICD-10, but only two SNPs remained after merging with these SNPs with 1000 Genome reference panel data, and both SNPs were not matched with the GWAS of IPF. Second, some comorbidities GWAS of IPF (i.e., OSA, GERD, COPD, PH, and lung cancer), failed to be adjusted in our multivariable MR model, which may have little impact on the overall causal estimates, but can increase the residual error and thus reduce the statistical efficiency. However, here we would like to follow the original multivariable MR work to emphasize that the main goal of MR-BMA method is, through model averaging procedure, to prioritize and select causal risk factors in a Bayesian framework from a set of candidate risk factors. Since the variable selection procedure often shrinks estimates towards the null, MR-BMA can lead to causal effect estimates being biased towards the null when there is a causal effect and unbiased estimates when there is no causal effect. Third, IPF is known to dramatically increase in prevalence with age\[51\], the use of summary rather than individual-level data from GWAS prevents direct estimation of the causal effect between hypothyroidism and age-stratified IPF. In addition, the IPF GWAS in this study was unable to adjust for age and gender due to these information not being available for all individuals in each dataset. Finally, the result from MR reflects the change in IPF risk due to a genetically predisposed (lifetime) change in hypothyroidism status, hence the short-term effect of hypothyroidism status on IPF risk merits additional investigation.

To conclude, our study rendered strong evidence of self-reported history of hypothyroidism/myxedema as a causal determinant on IPF risk, even when several other comorbidities of IPF were taken into account. Importantly, it is biologically plausible that hypothyroidism is embedded in the critical pathway for patients with IPF, for whom hypothyroidism should be considered and monitored closely. However, translating the findings into the treatment of IPF may be not straightforward, and experimental studies are certainly required for further validation.

### Data Sharing Statement

All data are available on the aforementioned public repository and are accessible with permission from the corresponding data committee. No restrictions on data availability other than those imposed by the corresponding data committee.

### Contributors

ZY, FX, and JJZ conceived the study. ZY obtained the genetic data. ZY, FX, JJZ and YZ verified all the data in the study. YZ performed the
analyses and interpreted the results. All authors contributed to the initial draft; JHZ and ZY made numerous revisions. All authors read and approved the final manuscript.

Declaration of Competing Interest
The authors declare no competing interests.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (81872712, 81673272, and 82173624), the Natural Science Foundation of Shandong Province (ZR2019ZD02) and the Young Scholars Program of Shandong University (2016WLJH23). We would like to thank Collaborative Group of genetic studies of IPF for providing us with the IPF GWAS summary data.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2021.103669.

References
[1] Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788–824.
[2] Neumark N, CC Jr, K-A Rose, N Kaminski. The Idiopathic Pulmonary Fibrosis Cell Atlas. Am J Physiol Lung Cell Mol Physiol 2020;319(6):L187–L92.
[3] Harari S, Davi M, Biffi A, Caminati A, Ghirardini A, Lavezzo V, et al. Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care. Emerg Med 2020;15(3):437–45.
[4] Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med 2018;379(19):1811–23.
[5] Raghu G, Anracto VS, Behr J, Stower SS. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal 2015;46(6):1113–30.
[6] Oldham JM, Collard HR. Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Front Med 2017;4:123.
[7] Oldham JM, Kumar D, Lee C, Patel SB, Takahashi-Mann A, Demchuk C, et al. Thyroid Disease is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest 2015;148(3):692–700.
[8] Sato Y, Tanino Y, Nakaiko T, Togawa R, Kawaiwata T, Wang X, et al. Clinical significance of thyroid hormone and antibodies in patients with idiopathic interstitial pneumonia. J Thorac Dis 2020;12(3):522–37.
[9] Awano N, Izumo T, Fukuda K, Ton M, Yamada D, Takemura T, et al. Is hypothyroidism in idiopathic pleuroparenchymal fibroelastosis a novel lung-thyroid syndrome? Respir Investig 2018;56(1):48–56.
[10] Bycroft C, Freytag C, Petkova D, Band G, Elliott DT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562(7726):203–9.
[11] Trumler A, Chaker L, Groeneweg S, Li Y, McAl攞Hugh R, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun 2018;9(1):4455.
[12] Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562(7726):203–9.
[13] Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, et al. High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. Int J Epidemiol 2021;50(3):891–901.
[14] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a powerful approach to multiple testing. Journal of the Royal statistical society: series B (Methodological) 1995;57(1):289–300.
[15] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60.
[16] Cook RD. Influential Observations in Linear Regression. Journal of the American Statistical Association 1979;74(365):167–9.
[17] Vavassor OS, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summary data. Int J Epidemiol 2017;46(6):1734–9.
[18] Santi A, Buette MM, Morreno RK, Menezes C, Bagatini MD, Schetinger MR, et al. Association of thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clin Chem Lab Med 2010;48(11):1635–9.
[19] Mancini A, Pigion P, Sottig S, Mangoni AA, Zinelu E, Prina P, et al. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review. Respir Med 2018;19(1):51.
[20] Mazzucco C, Crimi N, Vanezis C. Role of oxidative stress in pulmonary fibrosis. Monaldi Arch Chest Dis 2002;57(3–4):173–6.
[21] Mora AL, Bueno M, Rojas M. Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis: evidence-based guide-
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017;3:17074.

Alonso-Merino E, Martín Orozco R, Ruiz-Llorente L, Martínez-Iglesias OA, Velasco-Martín JP, Montero-Pedraza A, et al. Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses. Proc Natl Acad Sci U S A 2016;113(24):E3451–60.

Chaker L, Bianco AC, Jonklaas J, Hypothyroidism Peeters RP. Lancet 2017;390(10101):1550–62.

Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic Pulmonary Fibrosis. Annu Rev Pathol 2014;9:157–79.